Format

Send to

Choose Destination
See comment in PubMed Commons below
South Med J. 2004 Jul;97(7):699-701.

Topotecan-induced bronchiolitis.

Author information

1
Department of Internal Medicine, Madigan Army Medical Center, Tacoma, WA 98431, USA. colin.edgerton@nw.amedd.army.mil

Abstract

Topotecan HCl is an antitumor drug exhibiting topoisomerase 1-inhibitory activity. Topotecan is used in the treatment of metastatic carcinoma of the ovary and as second-line treatment of small-cell lung cancer. Reported dose-limiting adverse reactions to topotecan are primarily hematologic in nature. To date, only one other case of lung toxicity in a patient taking topotecan has been reported. The authors describe the development of obliterative bronchiolitis, as evidenced by radiographic and pulmonary function testing abnormalities, in a 61-year-old woman who presented with dyspnea, and who was receiving topotecan for peritoneal carcinomatosis.

PMID:
15301130
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Support Center